Innate Pharma (IPHA) Income towards Parent Company (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Income towards Parent Company data on file, last reported at -$24.2 million in Q2 2025.

• Quarterly Income towards Parent Company rose 9.4% year-over-year to -$24.2 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$103.7 million (down 19.11% YoY) and the FY2025 annual result came in at -$25.3 million, down 367.63% from the prior year.
• Income towards Parent Company rose to -$24.2 million in Q2 2025, from -$52.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $122.9 million in Q4 2021 to a low of -$52.9 million in Q4 2024.
• A 5-year average of $4.3 million and a median of -$8.1 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company soared 894.03% — and 2024, when it slumped 4411.67%.
• Tracing IPHA's Income towards Parent Company over 5 years: stood at $122.9 million in 2021, then slumped by 55.05% to $55.2 million in 2022, then sank by 114.74% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024, then jumped by 54.3% to -$24.2 million in 2025.
• The last three Income towards Parent Company figures came in at -$24.2 million (Q2 2025), -$52.9 million (Q4 2024), and -$26.7 million (Q2 2024), per Business Quant data.